BDD Pharma Ltd

Gamma scintigraphy is a powerful and versatile technology used to investigate the in-vivo performance of your drug or product. This non-invasive imaging technique allows us to follow the fate of the dosage form and administering it to a volunteer or patient. Not limited to just oral dosage forms, gamma sci...

•SWIFT accelerates evaluation and optimisation of product performance using in vivo clinical data to direct formulation design in real time.
•SWIFT studies enable you to make decisions on formulation changes based on emerging clinical data. • This integration of formulation development, GMP manufactu...

BDD has developed an erosion based controlled release technology that provides unrivaled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. ...

BDD has developed an erosion based controlled release technology that provides unrivalled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. The barrier layer is designed to erode at a controlled rate until eventually the drug is released from the core tablet, and the length of the delay period can be tailored between 2 and 8 hours by simply changing excipient ratios.

The barrier layer works independently of the core so can be applied to almost any drug where there is a therapeutic need, with minimal development. The release can be sustained or pulsed release giving unparalleled versatility.

The OralogiK barrier layer can be readily film coated, allowing addition of an immediate release dose which can be the same or different to the drug in the core tablet